Journal article icon

Journal article

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection

Abstract:
Introduction Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory illness in infants. There is no effective vaccine and the only effective treatment available is the monoclonal antibody palivizumab which reduces the risk of severe RSV disease in prematurely born infants. However, palivizumab is too costly to allow for wide implementation and thus treatment is restricted to supportive care. Despite extensive efforts to develop a vaccine, p... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.vaccine.2018.09.070

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Paediatrics
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Paediatrics
Role:
Author
Expand authors...
ReiThera SRL More from this funder
NIHR Oxford Biomedical Research More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Vaccine Journal website
Volume:
36
Issue:
46
Pages:
6988-6994
Publication date:
2018-10-11
Acceptance date:
2018-09-29
DOI:
EISSN:
1873-2518
ISSN:
0264-410X
Pmid:
30318168
Source identifiers:
928824
Language:
English
Keywords:
Pubs id:
pubs:928824
UUID:
uuid:3fbfa840-27b4-4cbe-915a-bb55fc1ef02f
Local pid:
pubs:928824
Deposit date:
2018-10-20

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP